Moderna files for health canada review of its respiratory syncytial virus (rsv) vaccine, mrna-1345

Mrna-1345 is an investigational vaccine for the prevention of rsv in adults aged 60 years or older toronto, on / accesswire / october 5, 2023 / moderna biopharma canada corp. today announced the filing of a new drug submission (nds) to health canada for mrna-1345, its investigational vaccine candidate for the prevention of rsv in adults aged 60 years or older. this is the first mrna vaccine candidate for rsv filed in canada.
MRNA Ratings Summary
MRNA Quant Ranking